Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › prochlorperazine

prochlorperazine

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of prochlorperazine

6 trials tracked of prochlorperazine: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 558 citations.

6Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 2
  1. Phase 4 The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine Completed · 558 cited
  2. Phase 4 Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine Completed · 79 cited
  3. Phase 3 Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer Completed
  4. Phase 3 Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial Completed
  5. Phase 2 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Completed
  6. Phase 2 E7 TCR T Cells for Human Papillomavirus-Associated Cancers Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Prochlorperazine Labeling: Indicated for Severe Nausea/Vomiting and Schizophrenia
Psychiatry FDA Approval
Prochlorperazine Labeling: Indicated for Severe Nausea/Vomiting and Schizophrenia The FDA approved a new injection to treat severe nausea and schizophrenia when pills cannot be taken
FDA labeling for prochlorperazine lists two approved indications: control of severe nausea and vomiting and treatment of schizophrenia.
A new FDA-approved injection now treats severe nausea and schizophrenia when patients cannot take pills by mouth.
FDA Apr 15, 2026